Aadi Bioscience Inc (WHWK): Earnings growth forecast for next year
Aadi Bioscience Inc (WHWK) specializes in oncology therapies. The promising EPS n+1 growth rate reflects market expectations, where the 2.70 mark records this metric. Aadi Bioscience Inc is establishing a closed-loop supply chain for the drug Fyarro. Management is focusing on commercial success and expanding the sales force. Research and development have shifted toward albumin nanoparticles to combat solid tumors.
WHWK (Aadi Bioscience): analytical breakdowns and indicator data
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- book capitalization indicators:
- debt and liquidity details:
Total Debt to Capital Aadi Bioscience Inc|WHWK - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Aadi Bioscience, Inc.|WHWK - Aggregate Debt Obligations|Debts to Book Capitalization Aadi Bioscience|WHWK - Company Long-Term Debt|Company Short-Term Debts Aadi Bioscience|Quick Liquidity aadibio.com
- earnings and valuation multiples information:
WHWK - Company Net Income|Expected Profit Aadi Bioscience Inc|WHWK - Business Payback Period|Forward P/E Multiple Aadi Bioscience, Inc.|WHWK - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Aadi Bioscience|WHWK - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Aadi Bioscience|WHWK - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months aadibio.com|WHWK - Earnings per share growth this year|Earnings growth forecast for next year Aadi Bioscience Inc
Fundamental company valuation:Aadi Bioscience Inc, WHWK
For the biotechnology sector, where Aadi Bioscience Inc (WHWK) implements strict ESG standards in the development of cancer therapies, fundamental stability is confirmed through the dynamics of expected returns. This assessment of future earnings per share growth aggregates daily analyst forecasts for net income over the coming year to identify deviations from target development rates. Steady adherence to the trend confirms the efficiency of resource management, while indicator volatility signals risks of profit shortfalls.
Key competitors
ONC (BeiGene Corp) - Earnings growth forecast for next year|Expected net earnings per share growth next year Halozyme Corp HALO|Earnings growth forecast for next year RVMD|Earnings growth forecast for next year ascentage.com (AAPG)|Earnings growth forecast for next year CGON (CG Oncology)|Earnings growth forecast for next year UroGen Pharma Ltd URGN|Bicara Bio - Earnings growth forecast for next year|PSNL (Personalis Genomics) - Projected earnings per share growth rate for next year|ERAS: Earnings growth forecast for next year|DCTH - Consensus forecast of earnings per share growth for next year|Expected earnings per share growth for next year YMAB|AURA: Expected earnings per share trend next year|Earnings growth forecast for next year CADL|Net earnings per share growth forecast for next year ARAY (Accuray, Inc.)|Earnings growth forecast for next year SLS (SELLAS Life Sciences Group)|Consensus forecast of earnings per share growth for next year actuatetherapeutics.com (ACTU)|CTOR - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year TuHURA Biosciences, Inc.|Protara (TARA) - Net earnings per share growth forecast for next year|FATE - Consensus forecast of earnings per share growth for next year|TCRX (TScan Therapeutics Inc) - Earnings growth forecast for next year|Expected earnings per share growth for next year Champions Oncology Corp (CSBR)|Earnings growth forecast for next year XBIT|Consensus forecast of earnings per share growth for next year cel-sci.com|Earnings growth forecast for next year OSTX (OS Therapies Inc)|radiopharmtheranostics.com (RADX) - Expected net earnings per share growth next year|ARTV - Net earnings per share growth forecast for next year|ANL (Adlai Nortye Ltd.) - Projected earnings per share growth rate for next year|VERU: Earnings growth forecast for next year|Expected earnings per share growth for next year Tempest Therapeutics Inc|XLO (Xilio Therapeutics Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year Enochian BioSciences RENB|Expected earnings per share growth for next year MURA (Mural Oncology plc)|KAPA (kairospharma.com) - Expected earnings per share trend next year|Earnings growth forecast for next year OKUR (OnKure Therapeutics)|Consensus forecast of earnings per share growth for next year CytoMed Therapeutics Ltd (GDTC)|CRIS - Net earnings per share growth forecast for next year|APLM (Apollomics, Inc.) - Projected earnings per share growth rate for next year|THAR: Earnings growth forecast for next year|Expected earnings per share growth for next year Advanced Biomed|Expected earnings per share growth for next year GNPX|Expected earnings per share growth for next year Calidi Bio (CLDI)|Earnings growth forecast for next year SBFM|XBIO (xeneticbio.com) - Expected earnings per share trend next year|Salarius Pharmaceuticals - Expected earnings per share growth for next year|PPBT - Expected earnings per share growth for next year|AONC - Net earnings per share growth forecast for next year|BGNE - Earnings growth forecast for next year|CKPT: Earnings growth forecast for next year|Expected earnings per share growth for next year elevationoncology.com|ICAD (iCAD Inc.) - Earnings growth forecast for next year|Earnings growth forecast for next year Ikena|Net earnings per share growth forecast for next year Notable Labs (NTBL)|viracta.com - Projected earnings per share growth rate for next year|Earnings growth forecast for next year MOR (MorphoSys Corp)|NAYA - Expected earnings per share growth for next year|Ascentage Pharma Group - Earnings growth forecast for next year
